Elevian is a biotechnology company focused on developing innovative treatments for stroke recovery. The company operates in the healthcare and pharmaceutical markets, targeting patients who have suffered from ischemic or hemorrhagic strokes. Elevian's lead product, rGDF11, is a recombinant protein designed to promote recovery of motor function by stimulating new blood vessel and neuron formation, as well as reducing inflammation. This approach addresses a significant gap in current stroke treatments, which are limited to the immediate hours following a stroke and do not promote long-term recovery. Elevian's business model involves conducting extensive research and clinical trials to bring rGDF11 to market, aiming to collaborate with healthcare providers and pharmaceutical companies for distribution and commercialization. Revenue is generated through product sales, licensing agreements, and potential partnerships with larger pharmaceutical firms.

Keywords: biotechnology, stroke recovery, rGDF11, recombinant protein, ischemic stroke, hemorrhagic stroke, neurogenesis, neovascularization, inflammation reduction, healthcare innovation.